Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease

Berta Canal1,*, Allison W. McClure1,*, Joseph F. Curran2,*, Mary Wu4, Rachel Ulferts3, Florian Weissmann1, Jingkun Zeng1, Agustina P. Bertolin1, Jennifer C. Milligan1, Souradeep Basu2, Lucy S. Drury1, Tom D. Deegan5, Ryo Fujisawa5, Emma L. Roberts2, Clovis Basier2, Karim Labib5, Rupert Beale3, Michael Howell4 and John F.X. Diffley1

1Chromosome Replication Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, U.K.; 2Cell Cycle Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, U.K.; 3Cell Biology of Infection Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, U.K.; 4High Throughput Screening, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, U.K.; 5The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Correspondence: John F.X Diffley (john.diffley@crick.ac.uk)

SARS-CoV-2 is a coronavirus that emerged in 2019 and rapidly spread across the world causing a deadly pandemic with tremendous social and economic costs. Healthcare systems worldwide are under great pressure, and there is an urgent need for effective antiviral treatments. The only currently approved antiviral treatment for COVID-19 is remdesivir, an inhibitor of viral genome replication. SARS-CoV-2 proliferation relies on the enzymatic activities of the non-structural proteins (nsp), which makes them interesting targets for the development of new antiviral treatments. With the aim to identify novel SARS-CoV-2 antivirals, we have purified the exoribonuclease/methyltransferase (nsp14) and its cofactor (nsp10) and developed biochemical assays compatible with high-throughput approaches to screen for exoribonuclease inhibitors. We have screened a library of over 5000 commercial compounds and identified patulin and aurintricarboxylic acid (ATA) as inhibitors of nsp14 exoribonuclease in vitro. We found that patulin and ATA inhibit replication of SARS-CoV-2 in a VERO E6 cell-culture model. These two new antiviral compounds will be valuable tools for further coronavirus research as well as potentially contributing to new therapeutic opportunities for COVID-19.

Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the human coronavirus disease 19 (COVID-19) [1,2]. The large number of infections and the severe and long-term consequences of COVID-19 have greatly burdened healthcare systems worldwide [3–6]. Lockdowns and ‘stay-at-home’ orders have been the only effective strategy to cut infections around the world, but they come with major societal and economic costs. Long-term solutions to the health and economic crises will rely on our ability to properly monitor the evolution of the pandemic, on the effectiveness of novel vaccines, and on the development of new antiviral treatments to prevent the loss of further lives until we are able to control infections globally [7,8].

Coronaviruses represent a threat to human health: in addition to SARS-CoV-2, two other coronaviruses, SARS-CoV-1 and MERS-CoV, have been responsible for severe human diseases this century [9]. Despite this, there is a lack of antiviral treatments for diseases caused by coronaviruses [10,11]. Currently, the only antiviral agent approved by regulatory agencies for treatment of COVID-19 is remdesivir, a delayed chain-terminator nucleotide analogue that impairs SARS-CoV-2 viral replication [12]. However, the WHO-funded Solidarity trial failed to identify increased survival or reduced hospitalisation time in
patients treated with remdesivir, casting doubt on its effectiveness in treating COVID-19 [13–16]. SARS-CoV-2 is a betacoronavirus of the order Nidovirales with a positive-sense RNA strand genome of ∼30 Kb that encodes multiple open reading frames (ORF) [17,18]. However, ORF1a and ORF1b represent two-thirds of the genome alone, and encode the 16 non-structural proteins of the virus (nsp1–nsp16) [17]. The nsps include the nine known viral enzymatic activities, which are highly conserved among coronaviruses and of special interest for the development of novel antiviral treatments, because of their important roles in viral replication and lifecycle [19].

Among them, nsp14 protein is a bifunctional enzyme with an N-terminal 3′ to 5′ exoribonuclease (ExoN) domain and a C-terminal S-adenosylmethionine (SAM)-dependent N7-methyltransferase (MTase) domain [20–22]. The ExoN domain belongs to the DEDD superfamily, which contains RNA and DNA exonucleases from all kingdoms of life, including the proofreading domains of some E. coli DNA polymerases [23–25]. While the MTase activity of nsp14 does not require a cofactor, the exonuclease activity of nsp14 is stimulated by the cofactor nsp10 [23,26].

It has been suggested that the exonuclease activity of nsp14 may act as a proofreader to reduce the mutation rate of the virus [27–33]. Considering that most RNA viruses possess small genomes and have high mutation rates, proofreading activity could be important to maintain the integrity of the unusually large RNA genomes of coronaviruses including SARS-CoV-2. Consistent with the hypothesis that nsp14 plays a role in proofreading during replication, it associates with the viral RNA-dependent RNA polymerase (RdRp) complex formed by nsp12 and its cofactors nsp7 and nsp8 [34,35]. Also, mutation of the ExoN domain of nsp14 in SARS-CoV-1 viruses resulted in viable viral progenies with high mutation rates [28,33]. However, similar ExoN mutations led to inviable virus progenies in MERS-CoV and SARS-CoV-2, suggesting that the exonuclease activity of nsp14 could have other essential roles in viral replication in these viruses [36]. Furthermore, coronavirus nsp14 exonuclease activity has been proposed to reduce the host innate antiviral immune response by cleaving viral-associated double-stranded RNAs [37,38] as well as to regulate viral genome recombination [39]. Thus, the exonuclease activity of nsp14 might be required for different aspects of viral genome replication and integrity and in other aspects of virus proliferation, making it an attractive target for the development of new antiviral treatments of COVID-19. Repurposing of previously characterised compounds for the treatment of novel diseases is a fast and efficient approach [40,41]. Here, we have purified the SARS-CoV-2 nsp14/nsp10 exonuclease and screened a custom collection of previously characterised compounds with the aim to identify novel COVID-19 antivirals.

Results

Purified SARS-CoV-2 nsp14/nsp10 functions as an exoribonuclease in vitro
To obtain sufficient quantities of active SARS-CoV-2 nsp14 exonuclease and nsp10 cofactor proteins for high-throughput screening, we tested a variety of protein tagging and expression strategies (Supplementary Tables S1 and S2). All protein purifications involved an initial step based on an affinity tag followed by at least one other purification step. We first expressed and purified nsp14 and nsp10 individually from Escherichia coli (E. coli) and baculovirus-infected Spodoptera frugiperda (S. frugiperda) insect cells (Figure 1A).

We tested nsp14 exonuclease activity using a double-strand RNA (dsRNA) substrate with 5′ overhangs of 7-nucleotides on both ends of the duplex, with one strand 5′ labelled with Cy5 (Cy5-dsRNA substrate) (Figure 1B). Reaction products were analysed on denaturing TBE-urea polyacrylamide gels, where generation of faster migrating products indicates enzymatic cleavage of the Cy5-dsRNA substrate at the recessed 3′ ends, resulting in the 3′-resection of the duplex. We did not observe cleavage of the Cy5-substrate in the presence of individual nsp14 purified from E. coli (Ec nsp14) and 3xFlag-6His-nsp14 purified from S. frugiperda insect cells (Sf FH-nsp14) proteins alone (Figure 1C). As expected, the addition of increasing amounts of the cofactor nsp10-6His-3xFlag expressed from insect cells (Sf nsp10-HF) promoted the nuclease activity of Ec nsp14 and, to a lesser extent, of Sf FH-nsp14 (Figure 1D). In contrast with other reports [26], N-terminal tagged nsp10 expressed from E. coli (Ec F-nsp10) was unable to stimulate nsp14 activity at similar concentrations (Figure 1D). This differs from previous results [26]; differences in expression and/or tagging strategies are likely to be responsible for this difference.

We also purified nsp14/nsp10 complexes co-expressed in E. coli and S. frugiperda insect cells (Figure 1E). When the nsp14 subunit harboured the affinity tag for purification, the nsp10 subunit was less abundant and, reciprocally, when the nsp10 subunit harboured the affinity tag for purification, the nsp14 subunit was less abundant, suggesting that the complex formed by nsp14 and nsp10 is not stable stoichiometrically, though it
Figure 1. Purified nsp14/nsp10 exoribonuclease assay.  
(A) Coomassie-stained SDS–PAGEs of purified nsp14 (60 kDa) and nsp10 (15 kDa) proteins. (B) Reaction scheme for gel-based exonuclease assay performed with the Cy5-substrate. Cleavage of the double-stranded RNA (dsRNA) substrate can be detected in denaturing TBE-urea polyacrylamide gels with the Cy5-oligonucleotide migrating faster as it is cleaved in the 3’ to 5’ direction. (C) Nuclease reactions containing 75 nM or 200 nM nsp14 purified from E. coli (Ec nsp14) or 3xFlag-6His-nsp14 purified from baculovirus-infected S. frugiperda insect cells (Sf FH-nsp14) and 50 nM Cy5-substrate. Reactions performed at RT for 30 min visualised by denaturing TBE-urea polyacrylamide gels. (D) As in C, lanes 1–8 show a titration of nsp10-6His-3xFlag purified from insect cells (Sf nsp10-HF) over 50 nM Sf FH-nsp14 or Ec nsp14 and lane 9 shows nuclease activity of 50 nM Ec nsp14 and 400 nM 3xFlag-nsp10 expressed from E. coli (Ec F-nsp10). (E) Coomassie-stained SDS–PAGEs of purified co-expressed nsp14 and nsp10 complexes. 3xFlag-nsp14/nsp10 purified from E. coli (Ec F-nsp14/nsp10) and nsp14/nsp10-His-3xFlag purified from insect cells (Sf nsp14/nsp10-HF). (F) As in C, titration of the co-expressed Ec F-nsp14/nsp10 complex and comparison to 50 nM Ec nsp14 + 400 nM Sf nsp10-HF. No (-) enzyme control was added as reference of the uncleaved substrate. (G) As in C, reactions containing 75 nM or 200 nM of the co-expressed complexes Sf nsp14/nsp10-HF and Ec F-nsp14/nsp10. Ec (expressed in E. coli), Sf (expressed in S. frugiperda insect cells).
remains possible that the expression system particularly influences the stoichiometry of the complex. Nevertheless, both nsp14/nsp10 complexes co-expressed in *E. coli* or insect cells showed nuclease activity comparable to the single Ec nsp14 + Sf nsp10-HF proteins (Figure 1F,G).

**Quantitative fluorescence assay for nsp14/nsp10 exoribonuclease activity**

To study nsp14/nsp10 exonuclease activity and perform a high-throughput screen, we developed a fluorescence-based assay using the intercalating Quant-it™RiboGreen RNA reagent (Figure 2A). We tested dilutions of RiboGreen against the Cy5-dsRNA substrate, and found a wide linear range of fluorescence using a 1/400 dilution of RiboGreen (Figure 2B and Supplementary Figure S1). RiboGreen fluorescence decayed after prolonged incubation in our reaction buffers (Figure 2C), so all subsequent experiments were analysed immediately after RiboGreen addition. To evaluate nsp14/nsp10 exonuclease activity with the RiboGreen assay, we took the samples (lanes 1–8) from Figure 1F and incubated them with RiboGreen. As predicted, RiboGreen fluorescence decreased with increasing amounts of 3xFlag-nsp14/nsp10 purified from *E. coli* (Ec nsp14/nsp10), consistent with exoribonuclease activity (Figure 2D).

**Nsp10–14 fusion functions as an efficient exoribonuclease**

The untagged subunit in the nsp14/nsp10 complex preparations tended to be substoichiometric (Figure 1E), and relatively high amounts of nsp10 were required to stimulate nsp14 (Figure 1D), suggesting that the nsp14/
nsp10 complex might not be stable. We, therefore, wondered if the direct fusion of nsp10 to nsp14 would generate a more active enzyme. A similar strategy was successful with the SARS-CoV-1 proteins nsp12/7/8, which purify as a more active polymerase complex when nsp7 and nsp8 are fused together with a short linker [34]. To test this, we expressed nsp14-linker-nsp10 (nsp14–10) and nsp10-linker-nsp14 (nsp10–14) fusion proteins in E. coli (Figure 3A,B). The nsp10–14 fusion cleaved the Cy5-dsRNA substrate in both the gel and RiboGreen assays (Figure 3C). Titration of nsp10–14 fusion protein showed high exonuclease activity with as little as 1–3 nM of protein compared with ∼200 nM needed for the nsp14/nsp10 co-expressed complex (Figure 1F, 2D and 3D). The nsp14–10 fusion protein also showed high exonuclease activity (Figure 3D). To avoid any interference between Cy5 and RiboGreen, we then titrated the nsp10–14 fusion in the presence of an unlabelled version of the Cy5-dsRNA substrate (Figure 2A and Supplementary Table S3), which resulted in exonuclease activity (Figure 3E) comparable to that observed with the Cy5-substrate (Figure 3D). Nsp14 is also an N7-guanine cap methyltransferase and the nsp10–14 fusion retains this methyltransferase activity (Supplementary Figure S2).

Figure 3. The nsp14–10 fusion protein is an efficient exonuclease.
(A) Schematic of nsp14–nsp10 and nsp10–nsp14 fusion proteins. (B) Coomassie-stained SDS–PAGEs of purified nsp14–nsp10 (nsp14–10) and nsp10–nsp14 (nsp10–14) fusion proteins from E. coli (75 kDa). Connecting linker is GGSGGS. (C) Time course of exonuclease reaction containing 5 nM nsp10–14 fusion and 50 nM Cy5-double-stranded RNA (dsRNA) substrate. Reactions were split in half and separated on TBE-urea polyacrylamide gels or incubated with RiboGreen. No (-) enzyme control was added as reference of the uncleaved substrate. Gel and graph show values of a single experiment. (D) Exonuclease reactions containing a titration of nsp10–14 and nsp14–10 fusion proteins and 50 nM Cy5-dsRNA substrate performed for 30 min. Graph shows values of a single experiment. (E) Titration of nsp10–14 fusion in exonuclease assay with 50 nM unlabelled dsRNA substrate after 30 min detected by RiboGreen. Error bars represent standard deviation of triplicate values of a single experiment. (a.u. = arbitrary units).
Screens for SARS-CoV-2 nsp14/nsp10 exonuclease inhibitors

The quantitative nature of the RiboGreen assay enabled us to determine the Michaelis–Menten constant ($K_M$) of the nsp10–14 fusion protein for the unlabelled dsRNA substrate to be 66 nM (Supplementary Figure S3A,B). We then carried out a high-throughput screen to identify nsp14/nsp10 exonuclease inhibitors from a custom library of over 5000 commercial compounds (see Zeng et al. [42] for contents and description of the library). The screen had a robust signal to noise ratio between positive and negative controls, and a mean $Z'$ factor of 0.72, and we detected many compounds apparently able to reduce nsp14/nsp10 exonuclease activity at both concentrations screened (Supplementary Figure S3C). In the RiboGreen assay, fluorescence is highest at time zero of the exonuclease reaction, and cleavage of the substrate leads to reduced fluorescence signals (Figure 2D or 3D as examples). Thus, inhibition of exonuclease activity is expected to decrease the cleavage-dependent reduction in RiboGreen fluorescence. Based on this, to identify putative inhibitors of nsp14/nsp10 exonuclease, we selected compounds that led to higher final fluorescence signals than control reactions. However, when we were validating these compounds, we found that many were auto-fluorescent in the wavelength range of RiboGreen fluorescence (Supplementary Figure S3D). Because of this, we could not feasibly distinguish true hit compounds from auto-fluorescent false hits using this approach.

We decided to perform a second fluorescence-based high-throughput screen against the same library but using a different assay which utilises a different wavelength. For the new assay, we used an RNA duplex substrate with a 20-nucleotide 5' overhang, conjugated to a Cy3–quencher pair (Figure 4A and Supplementary Table S3). Using this substrate, nucleolytic cleavage by nsp10–14 fusion protein released the Cy3 fluorophore strand from the quencher strand and produced a fluorescent signal (Figure 4A,B). When a DNA version of this substrate was used, only background levels of fluorescence were detected (Figure 4B). This indicated that, as expected, nsp10–14 is unable to cleave DNA substrates and that the fluorescence in reactions with the Cy3-dsRNA substrate is not due to unspecific factors such as temperature-dependent unwinding. When using this substrate, we were able to obtain kinetic data of the enzyme compared with the end-point information obtained when using our previous RiboGreen approach. We, thus, monitored fluorescence over time and titrated the substrate, which gave an estimated $K_M$ of 40 nM (Figure 4C,D). The estimated $K_M$ was similar to our previous estimation using the RiboGreen assay (66 nM) (Supplementary Figure S3A,B), and therefore we decided to perform this second screen using 50 nM of the substrate, as we did in the first screen. At 50 nM of the substrate, we assessed nuclease activity over a range of enzyme concentrations and chose to do the reactions in the screen for 10 min with 0.5 nM of nsp10–14 fusion protein (Figure 4E).

As performed in the first screen, the drug library was screened at 1.25 μM and 3.75 μM. First, nsp10–14 was incubated with the compounds for 10 min prior to the addition of the substrate, then fluorescent measurements were taken every minute for 10 min. The activity of nsp10–14 was defined as the slope of the reaction over the linear range. Again, the screen had a robust signal to noise ratio between positive and negative controls and a mean $Z'$ factor of 0.86. The activity of nsp10–14 was normalised to the control wells without compounds (see Experimental procedures). Both compound concentrations produced hits with residual activities less than 1 (Figure 4F). We considered compounds that reduced nsp10–14 activity below 80% in both concentrations, showed a Z score less than −5 (Figure 4G), and also showed some reduction in the first screen with RiboGreen detection. We also considered compounds that showed stronger inhibition in the higher dose in both screens, even if the absolute inhibition was not as strong as our initial cut-offs. We discounted some compounds for having a high aggregation index (>3 or known aggregators) [43] and for appearing in multiple screens [44–49].

Validation of hits

Taking the results from both screens into consideration, we tested 12 compounds in validation experiments (Supplementary Table S4). We returned to the gel-based assay with the Cy5-dsRNA substrate for validation. The nsp10–14 fusion protein was incubated with the hit compounds for 10 min prior to substrate addition as in the screens, and the reactions were stopped at 5 min instead of the usual 30 min reactions, to allow for the visualisation of both the full-length RNA strand and the cleaved products. The non-ionic detergent Tween 20 was included in these experiments (as well as in all previous experiments and screens) to reduce compound aggregation as described in our accompanying manuscript (Zeng et al. [42]) and others [50,51]. Two compounds inhibited nsp10–14 exonuclease activity in a concentration-dependent manner at both 5 μM and 25 μM: patulin and aurantricarboxylic acid (ATA) (Figure 5A). We also tested whether patulin inhibited the
Figure 4. High-throughput screen to identify SARS-CoV-2 nsp14/nsp10 exoribonuclease inhibitors. Part 1 of 2

(A) Reaction scheme for the kinetic nuclease assay performed with the Cy3-double-stranded RNA (dsRNA) substrate (Cy3-substrate). Cleavage of the Cy3-dsRNA substrate by nsp14/nsp10 nuclease can be detected by the appearance of Cy3
Figure 4. High-throughput screen to identify SARS-CoV-2 nsp14/nsp10 exoribonuclease inhibitors. Part 2 of 2

fluorescence. (B) Exonuclease reactions containing 5 nM nsp10–14 fusion protein and 180 nM Cy3-dsRNA substrate or 180 nM Cy3-dsDNA substrate and detected after 1 h. Error bars represent standard deviation from mean of triplicate values of a single experiment. (C) Cy3-dsRNA substrate titration (15–500 nM) performed in the presence of 0.5 nM nsp10–14 with fluorescence monitored over time. Error bars represent standard deviation from mean of triplicate values of a single experiment. (D) Non-linear fit to Michaelis–Menten equation of slopes from C. Error bars represent standard deviation from mean of triplicate values of a single experiment. (E) Titration of nsp10–14 with 50 nM Cy3-dsRNA substrate. Error bars represent standard deviation from mean of triplicate values of a single experiment. (F) Normalised residual activity of screen sample wells in low and high concentrations. (G) Z-scores of samples plotted as low versus high concentration. In all panels, error bars represent standard deviation from the mean. (a.u. = arbitrary units).

copurified complex nsp14/nsp10 in addition to nsp10–14 fusion protein. Indeed, patulin inhibited both fusion and complex when in ~5000 fold excess of the enzyme (Figure 5B,C lanes 2–5, and Supplementary Figure S4A).

To determine how specific patulin and ATA are to nsp10–14, we tested whether they inhibited other nucleases such as RNase A and benzonase. We titrated RNase A and benzonase to select enzyme concentrations that allowed us to visualise both full-length RNA and cleaved products in gel-based assays after 5 min (Supplementary Figure S4B). Patulin did not inhibit RNase A or benzonase up to 50 μM, suggesting that it is not a general nuclease inhibitor (Figure 5C). Despite the fact that ATA has been described as a general inhibitor of nucleases and other DNA binding enzymes [52], we observed only minor inhibition of RNase A and benzonase at 50 μM ATA (Figure 5D). In contrast, we observed inhibition of nsp10–14 from 5 μM ATA, indicating that it inhibits nsp10–14 at lower concentrations than it inhibits RNase A and benzonase (Figure 5D).

To characterise the inhibition kinetics of patulin and ATA (chemical structures in Supplementary Figure S4C,D) on nsp14/nsp10 exonuclease, we determined the half-maximal inhibitory concentration (IC50) of these compounds. To calculate the IC50, we incubated increasing concentrations of patulin or ATA with nsp10–14 protein following the scheme of the screen and calculated the exonuclease activity of nsp10–14 at each drug concentration in the presence of the Cy3-dsRNA substrate (see Experimental procedures). Patulin showed an IC50 of 1.8 μM (95% CI 1.6–2.1 μM) and ATA showed an IC50 of 10.3 μM (95% CI 8.6–12.1 μM) (Figure 5E,F and Supplementary Figures S4E,F). Importantly, in all the concentrations assayed, patulin and ATA do not quench Cy3 fluorescence (Supplementary Figures S4G,H).

Effects of patulin and aurantricarboxylic acid on viral growth

To explore if patulin and ATA could serve as antiviral drugs against SARS-CoV-2, we performed infectivity assays using VERO E6 cells in the presence of increasing concentrations of patulin and ATA. SARS-CoV-2 nsp14 exonuclease activity has been recently proposed to be essential for viral proliferation, and thus we expected that if patulin and ATA were able to inhibit nsp14 exonuclease also in cells, we would observe reduced viral infectivity [36]. Virus in VERO E6 cells 22 h post-infection (MOI 0.5 PFU/cell) was detected by immunofluorescence with an antibody raised against the SARS-CoV-2 nucleocapsid (N) protein (see Experimental procedures). Viral proliferation was reduced in the presence of patulin at ~5–10 μM (Figure 6A, B). Above 10 μM, patulin decreased cell viability of cultured VERO E6 (Figure 6A,B). Similarly, we observed reduced viral proliferation in the presence of ATA in a dose-dependent manner from ~3 to 100 μM (Figure 6C). At the concentrations tested, ATA did not affect cell viability (Figure 6C).

Combining different antivirals is effective in treating viral infections and reducing treatment resistance [53]. To this end, we performed the SARS-CoV-2 infectivity assays in the presence of patulin or ATA in combination with the SARS-CoV-2 antiviral remdesivir. When combined, the dose–response curves of patulin and ATA were not shifted in response to a low dose (0.5 μM) of remdesivir, indicating that, under the conditions tested, these drugs do not synergise (Figure 6D,E). We also performed the reciprocal experiment testing whether patulin would alter the remdesivir dose–response curve, but we did not observe any shift in the remdesivir curve in the presence of 3 μM or 5 μM patulin (Supplementary Figure S5).

Discussion

Previously, nsp14/nsp10 exonuclease activity had only been studied by monitoring cleavage of RNA substrates in gel-based assays using an excess of enzyme over substrate concentration [26,36,54,55]. We have purified
Figure 5. Patulin and aurintricarboxylic acid (ATA) inhibit nsp14/nsp10 nuclease in vitro.

(A) Nuclease reactions containing 1 nM nsp10–14 fusion protein and 50 nM of Cy5-dsRNA substrate alone or in the presence of 25 μM or 5 μM of each of the 12 top hits (in blue) selected from both HTS screens. Reactions were performed for 5 min at RT and visualised by TBE-urea polyacrylamide gels. No (-) enzyme control was added as reference of the uncleaved substrate. (B) 1 nM nsp10–14 fusion or 200 nM co-expressed Ec F-nsp14/nsp10 complex was pre-incubated with the specified concentration of patulin, and nuclease reactions were performed in the presence of 50 nM Cy5-dsRNA substrate for 5 min and visualised by TBE-urea polyacrylamide gels. No (-) enzyme control was added as reference of the uncleaved substrate. (C,D) Nuclease reactions containing 1 nM nsp10–14 fusion protein, 0.06 ng/μl RNase A (Qiagen) and 0.5 mU/μl benzonase (Sigma) nucleases and 50 nM Cy5-dsRNA substrate in the presence of 0, 5, 25 or 50 μM patulin (C) or ATA (D). High and low image saturations are shown. No (-) enzyme control was added as reference of the uncleaved substrate. (E,F) Dose–response curves and IC₅₀ values of
patulin (E) and ATA (F). IC₅₀ values were calculated as described in Experimental Procedures. Nuclease activities (slope) for each patulin and ATA concentration were obtained from triplicate kinetic reactions (20 min) in the presence of 0.5 nM nsp10–14 fusion and 50 nM Cy3-substrate (Supplementary Figures S4E, S5F). Patulin and ATA were pre-incubated with nsp10–14 for 10 min prior to the addition of the substrate. Graphs represent % of control activity (slope) vs. the log₁₀ of the concentration of patulin or ATA. Error bars represent standard deviation from the mean of triplicate values of a single experiment. ATA (Aurintricarboxylic acid), PBIT (Phenylene-1,3-bis(ethane-2-isothiourea) dihydrobromide). Ec (expressed in E. coli).

**nsp14 and nsp10 proteins from E. coli and from S. frugiperda insect cells and shown that both expression systems can be used to produce active nsp14/nsp10 exoribonuclease (ExoN). With the aim to obtain enough active protein to perform the screen, we developed multiple parallel tagging strategies and observed reduced exonuclease activity for some of them; however, further work will be required to characterise the relevance of the type, position and presence of specific tags and the protein expression system in the formation of the nsp14/nsp10 complex and its exonuclease activity. We have purified a fusion protein of nsp14 and nsp10 that shows ~100 fold higher exonuclease activity than the co-expressed or single nsp14 and nsp10 proteins.

Furthermore, we developed fluorescence-based assays for nsp14/nsp10 exoribonuclease activity in solution, which are also scalable for high-throughput screens. We used these assays and the nsp10–14 fusion protein to screen for nsp14/nsp10 exoribonuclease inhibitors among a custom chemical library of over 5000 commercial compounds and identified patulin and ATA as inhibitors of SARS-CoV-2 nsp14/nsp10 exoribonuclease. Using the same chemical library, a screen to identify nsp14 methyltransferase (MTase) inhibitors has been carried out in parallel (see Basu et al. [56]). Together, the inhibitors identified in these studies provide novel tools for specific inhibition of the individual activities of this multi-functional enzyme.

The *in vitro* inhibitors of nsp14/nsp10 ExoN identified in our high-throughput screen, patulin and ATA, reduced viral proliferation in cell-based assays. This is consistent with the ExoN activity being essential for SARS-CoV-2 proliferation [36]. Further studies are required to establish whether the effect of the inhibitors is via direct inhibition of nsp14/nsp10 ExoN, such as rationally designing drug-resistant nsp14/nsp10 mutations, or testing the activity of the inhibitors against other viruses. Also, our assays were performed with VERO E6 cells, a commonly used Green Monkey *Chlorocebus sabaeus* cell line, and it would be interesting for future studies to test patulin and ATA in human cell models of SARS-CoV-2 infection.

The exoribonuclease domain of nsp14 is highly conserved among the nidoviruses that possess large genomes (>20 Kb). However, the function of ExoN for viral proliferation is still unclear. In addition to its proposed role as proofreader, nsp14/nsp10 is thought to promote host innate immune evasion by cleaving dsRNA molecules and participate in viral genome recombination [37,39,57,58]. ExoN is essential in SARS-CoV-2 [36] and therefore, patulin and ATA represent new tools to acutely inhibit ExoN activity during viral growth, which should be valuable for understanding the role of nsp14/nsp10 ExoN during the viral life cycle. Also, considering the role of nsp14/nsp10 in immune suppression, we speculate that even mild inhibition of nsp14/nsp10 ExoN by patulin and ATA could lead to the accumulation of highly immunogenic dsRNA molecules and promote strong immune antiviral responses. It would be interesting for future studies to measure and sequence the dsRNA molecules to better characterise the physiological role of nsp14/nsp10 ExoN function. Coronavirus nsp14 has been proposed to modulate viral replication and host immune responses also via interaction with host components [37,59–62]. Further work will be required to understand the involvement of the ExoN and MTase activities in such host interactions, and the use of the novel nsp14 inhibitors to modulate them.

A proofreader activity of nsp14 could reduce the effectiveness of nucleotide analogue chain terminators such as remdesivir by preventing their incorporation or removing them [63]. Supporting this, ExoN mutants of the coronavirus murine hepatitis virus (MHV) were shown to have a higher sensitivity to remdesivir treatment [12]. However, our results in VERO E6 cells did not show any synergy of patulin or ATA with remdesivir (Figure 6D,E). Remdesivir acts as a delayed chain terminator where RNA synthesis stops about 3 nucleotides after its incorporation and perhaps nsp14/nsp10 does not have access to remove it. It would be interesting for future studies to examine whether patulin and ATA synergise with immediate chain terminators and to further explore how nsp14/nsp10 might act as a proofreader.

ATA has been used as a positive control drug for nuclease inhibition due to its known roles as a general nuclease and DNA binding inhibitor [52,64]. Indeed, ATA has recently been used as a control to inhibit nsp14/nsp10 exoribonuclease using a biochemical gel-based assay [65]. However, our results show that ATA
Figure 6. Patulin and aurintricarboxylic acid (ATA) inhibit SARS-CoV-2 viral growth in VERO E6 cells.

(A) After VERO E6 cell seeding, media was replaced with fresh media containing indicated concentrations of patulin followed by infection with SARS-CoV-2. Twenty-two hours post-infection, wells were stained with DRAQ7 (cells) and AlexaFluor-conjugated antibodies against the SARS-CoV-2 N protein (virus). Quantification of triplicate values of a single experiment is shown at right (mean ± SD). Viral area quantification is normalised to cell area. (B) Experiment performed as in A with lower dose titration of patulin. (C) Experiment as in A, with titration of aurintricarboxylic acid (ATA). (D) Experiment as in A, with combined treatment of 0.5 μM remdesivir. Note the black line indicating patulin only treatment is the same as in A. (E) Experiment as in C, with combined treatment of 0.5 μM remdesivir. Note the black line indicating ATA only treatment is the same as in C.
inhibits nsp14/nsp10 exoribonuclease activity at much lower concentrations than the concentration needed to inhibit other nucleases such as RNase A and benzonase (Figure 5D), suggesting that ATA has specific activity towards SARS-CoV-2 nsp14/nsp10 compared with other nucleases. We cannot rule out the possibility that some of the antiviral activity of ATA is due to inhibition of other nucleases besides nsp14/nsp10. ATA has been shown to inhibit replication of several other viruses including SARS-CoV-1 and Zika [66,67], and studies using cell-culture and animal models have shown limited toxicity of ATA [67–69]. Further studies will be needed to understand the putative use of ATA for the inhibition of SARS-CoV-2 and treatment of COVID-19.

Patulin is a lactone mycotoxin produced by several species of *Penicillium* and *Aspergillus*, commonly found in foodstuffs such as rotting apples [70]. Patulin has antimicrobial effects and it has been shown to have cytotoxic, apoptotic and genotoxic effects in mammalian cells, including cancer cells [70–73]. While patulin does show some cellular toxicity in our assays, structural analogues of patulin were shown to have reduced toxicity compared with patulin in cell culture models [74], providing an opportunity to study alternative patulin-like molecules for the development of novel antiviral agents against coronaviruses. Also, considering that even mild inhibition of nsp14/nsp10 exonuclease could have an effect on host immune responses, low and transient doses of patulin could also be considered. After some initially promising results in the early 20th century, patulin was tested in a clinical trial for its ability to treat the common cold but found to be ineffective [75]. Since the time of this MRC trial, it has been shown that many viruses in addition to coronaviruses can cause the common cold, so it is likely that if patulin was effective only in treating coronavirus-based colds, the trial would not have uncovered it. It will be interesting for future studies to test patulin in the treatment of both COVID-19 and other coronavirus diseases.

**Materials and methods**

**Expression constructs and protein expression in *E. coli***

The sequences of SARS-CoV-2 nsp14 and nsp10 (NCBI reference sequence NC_045512.2) were codon optimised for expression in *E. coli* using the GeneArt Gene Synthesis software (ThermoFisher scientific) and genes were ordered from GeneWiz (codon optimised DNA sequences in supplementary information). The HiFi DNA Assembly system (NEB) was used to build the plasmids to express individual, complex and fusion proteins (Supplementary Table S1). *Individual nsp10* was expressed from plasmid pET11a_3xFlag-nsp10 (SARS-CoV-2) (Addgene Id 169157) (Ec F-nsp10) containing the N-terminal 3xFlag tag (MDYKDHDGDYKDHDIDYKDDDDK) followed by the predicted nsp5 protease cleavage site found between nsp9 and nsp10 [VRLQ]. Untagged *individual nsp14* (Ec nsp14) was purified from plasmid pK27SUMO_14His-SUMO-nsp14 (SARS-CoV-2) (MRC PPU Id DU70487) that contains non-codon optimised nsp14 gene cloned into plasmid pK27SUMO (gene synthesis at MRC PPU, available from https://mrcppu-covid.bio). To co-express nsp14/nsp10 complex (Ec F-nsp14/nsp10), we co-transformed plasmids pCOLADuet-1_nsp10 (SARS-CoV-2) (Addgene Id 169158) and pET11a_3xFlag-nsp14 (SARS-CoV-2) (Addgene Id 169159). Plasmid 169159 contains the predicted nsp5 protease cleavage site found between nsp13 and nsp14 [VATLQ] between the N-terminal 3xFlag tag and nsp14 sequence. To express nsp10–nsp14 and nsp14–nsp10 fusion proteins, nsp10 and nsp14 genes from plasmids 169157 and 169159 were cloned in frame with the N-terminal 14His-SUMO tag of plasmid pK27Sumo [76], including a GGSGGS linker between both nsp proteins (Figure 3A), generating plasmids pK27SUMO_14His-SUMO-nsp14-GGSGGS-nsp10 (SARS-CoV-2) (Addgene Id 169160) and pK27SUMO_14His-SUMO-nsp10-GGSGGS-nsp14 (SARS-CoV-2) (Addgene Id 169161).

For expression of the nsp10–nsp14 fusion protein, T7 Express LysY competent cells from NEB (C3010I) were transformed with plasmid 169161 (Supplementary Table S1) and grown overnight (ON) at 37°C in LB media supplemented with 50 μg/ml kanamycin. Saturated cultures were diluted in 10 l to an OD595 of 0.1 and grown at 37°C until OD595 of 0.4. Cultures were then cooled down to 16°C on ice, after which protein expression was induced ON at 16°C by adding 0.4 mM IPTG. Cells were harvested by centrifugation, washed once in 1× TBS, and the pellet was frozen in liquid nitrogen. All steps after this point were carried out at 4°C. Pellets were resuspended to 30 ml with lysis buffer (50 mM Tris–HCl pH 7.5, 0.05% NP-40, 10% glycerol, 500 mM NaCl, 1 mM DTT and 30 mM imidazole) + complete™ EDTA-free Protease Inhibitor Cocktail (Sigma). Cells were lysed for 30 min on ice by addition of 0.33 mg/ml lysozyme followed by sonication (5 s on/5 s off at 35% for 3 min) and cell debris was cleared by centrifugation at 20,000 rpm for 30 min.

**Expression constructs and protein expression in baculovirus-infected insect cells**

Plasmids pBIG1b_nsp10-6His-3xFlag (SARS-CoV-2) (Addgene Id 169162) (Sf nsp10-HF), pBIG1a_3xFlag-6His-nsp14 (SARS-CoV-2) (Addgene Id 169163) (Sf FH-nsp14) and pBIG2ab_nsp10-6His-3xFlag
was added to the cleared lysate and rotated for 2 h. The resin was eluted at 0.02% NP-40, 10% glycerol, 1 mM DTT and 1000 mM NaCl. The nsp14 fusion protein concentration was at 1.1 mg/ml (yield ~0.4 mg protein/l cell culture).

Modifications of this protocol were used to purify the other recombinant proteins (Supplementary Table S1). Purifications using 3xFlag tag were performed similarly with the following modifications: 1 ml slurry of ANTI-FLAG M2 Affinity gel (Sigma) equilibrated in flag lysis buffer (50 mM Tris–HCl pH 7.5, 0.05% NP-40, 10% glycerol, 500 mM NaCl, 1 mM DTT) was added to the cleared lysate and rotated for 2 h. The resin was collected by centrifugation at 1000×g for 2 min, washed with 100 ml lysis buffer and incubated for 30 min in 10 ml elution buffer (50 mM Tris–HCl pH 7.5, 0.05% NP-40, 10% glycerol, 200 mM NaCl, 1 mM DTT) + 20 μg/ml Ulp1-cat-6His, and passed over 0.5 ml HisPur™-Ni-NTA resin pre-equilibrated in dialysis buffer to remove Ulp1. The flowthrough was applied to a MonoQ (5/50 GL, GE healthcare) equilibrated in Buffer 100 (25 mM Tris–HCl pH 7.5, 0.02% NP-40, 10% glycerol, 1 mM DTT and 100 mM NaCl), washed with 10 CV Buffer 100 and eluted over a 20 CV linear gradient to Buffer 1000 (25 mM Tris–HCl pH 7.5, 0.02% NP-40, 10% glycerol, 1 mM DTT and 1000 mM NaCl). The nsp14–10 and nsp10–14 fusion proteins eluted at ~400 mM NaCl. Peak fractions were pooled, concentrated to ~0.4 ml with a 30KDa Amicon Ultra Centrifugal filter and separated in a Superdex 200 Increase 10/300 GL column equilibrated in Buffer 150 (25 mM Tris–HCl pH 7.5, 0.02% NP-40, 10% glycerol, 1 mM DTT, 4 mM MgCl2 and 150 mM NaCl). Peak fractions were pooled, aliquoted and frozen in liquid nitrogen to be stored at −80°C. Protein concentration was determined by Bradford and by comparing to a BSA standard curve on a Coomassie stained SDS–PAGE gel. The nsp10–14 fusion protein concentration was at 1.1 mg/ml (yield ~0.4 mg protein/l cell culture).

Expression and purification of Ulp1-cat-6His protease

T7 Express LysY competent cells transformed with plasmid pFGET19-Ulp1 (Addgene Id 64697) were grown to OD_{595} of 0.8 at 37°C in 21 LB media supplemented with 50 μg/ml kanamycin (ON culture at 37°C without shaking). Expression was induced for 4 h at 37°C with shaking by the addition of 1 mM IPTG. Pellet was resuspended in lysis buffer (50 mM Tris–HCl pH 8, 0.02% NP40, 10% Glycerol, 500 mM NaCl, 5 mM MgOAc, 1 mM DTT) + 20 mM imidazole + protease inhibitors (10 μg/ml Pepstatin - P4265 Sigma-, 10 μg/ml Leupeptin -108975 Merck-, 1 mM AEBSF -A8456 Sigma-) and cells were lysed by lysozyme and sonication. 0.5 ml slurry of HisPur™-Ni-NTA resin equilibrated in lysis buffer was added to the cleared lysate and rotated for 1 h at 4°C before washing with 50 ml lysis buffer and eluted in lysis buffer + 250 mM imidazole. Eluate was concentrated to ~0.4 ml with a 10KDa Amicon Ultra Centrifugal filter and separated in a Superdex200 Increase 10/300 GL column equilibrated in storage buffer (50 mM Tris–HCl pH 8, 0.01% NP40, 10% Glycerol, 500 mM NaCl, 5 mM MgOAc, 0.5 mM TCEP).
Peak fractions were pooled, and aliquots were frozen in liquid nitrogen and stored at −80°C. Ulp1 eluted at ∼13 ml, and protein concentration was determined by Bradford at 2 mg/ml.

**Ribogreen exonuclease assay**

For substrate preparation, oligos i (unlabelled) and iii (unlabelled) (Supplementary Table S3) were diluted to 100 μM in RNase-free water, then mixed to a final concentration of 10 μM each in 20 mM Tris–HCl (pH 7.5) and 50 mM NaCl in 50 μl. Mix was heated at 98°C for 2 min and then cooled to 4°C in 700 cycles of 4 s each (−0.1°C/cycle).

End-point nuclease assays (20 μl) were performed at room temperature (RT) in reaction buffer 1 (25 mM Tris–HCl pH 7.5, 0.02% Tween20, 10% glycerol, 1.5 mM MgCl2, 20 mM NaCl, 0.1 mg/ml BSA and 0.5 mM TCEP). Enzyme and substrate were diluted in reaction buffer 1 at the concentration specified in each figure legend. Reactions were stopped by the addition of 30 μl Stop/RiboGreen mix (25 mM Tris–HCl pH 7.5, 0.1 mg/ml BSA, 20 mM EDTA and a 1/250 dilution of Quant-iT™ RiboGreen® RNA reagent, ThermoFisher Scientific) after which fluorescence was read in black 384-well plates (GRE384fb 781076) using a Spark Multimode microplate reader (Tecan) with the following settings: Excitation 485 nm/Emission 530 nm (20/20 bandwidth), Gain 94, 30 flashes, Z position of 18843.

**Cy5 gel-based exonuclease assay**

Substrate preparation was performed as for the RiboGreen assay, using oligos ii (Cy5) and iii (unlabelled) (Supplementary Table S3). End-point nuclease assays were performed essentially as the RiboGreen assays except that reactions were stopped (1 : 1) with 2x sample buffer (98% Formamide, 10 mM EDTA). Samples were denatured at 95°C for 2 min and loaded on 7M-urea polyacrylamide-1× TBE denaturing gels and run in 1× TBE running buffer at 180 V for 2–3 h at RT before Cy5 fluorescence was visualised with an Amersham Imager 600, GE lifesciences.

**Cy3/quencher-based exonuclease assay (kinetic)**

For Cy3-substrates preparation, RNA oligos iv (Cy3) and v (quencher) or DNA oligos vi and vii were mixed at a 1 : 1.2 ratio with Cy3 oligo to 20 μM and Iowa Black RQ quencher oligo to 24 μM (Supplementary Table S3). For RNA substrate, samples were heated at 75°C for 3 min and then cooled to 5°C in 700 cycles of 4 s each (−0.1°C/cycle) after which substrate was aliquoted and stored at −20°C. For DNA substrate, samples were heated at 95°C for 5 min and then cooled down to 21°C in 740 cycles of 1 s each (−0.1°C/cycle), aliquoted and stored at −20°C.

Cy3/quencher-based kinetic nuclease assays (20 μl) were performed at room temperature (RT) in reaction buffer 2 (50 mM Tris–HCl pH 7.5, 0.01% Tween20, 10% glycerol, 1.5 mM MgCl2, 20 mM NaCl, 0.1 mg/ml BSA and 0.5 mM TCEP). Enzyme and substrate were diluted in reaction buffer 2 at the concentration specified in each figure legend. Progression of the reactions was monitored every min by fluorescence in black 384-well plates (GRE384fb 781076) using a Spark Multimode microplate reader (Tecan) with the following settings: Excitation 545 nm/Emission 575 nm (10/10 bandwidth), Gain 147, 10 flashes, Z position of 17800.

**Methyltransferase assay**

The methyltransferase activity of nsp10–14 was assayed by the detection of released SAH from the methyltransferase reaction. Released SAH was detected through the use of the commercially available EPIgeneous™ methyltransferase kit (CisBio Bioassays). Individual kit reagents were reconstituted according to the manufacturer’s instruction. The methyltransferase reaction was conducted at room temperature in an 8 μl reaction volume with 10 nM nsp10–14, 1 μM Ultrapure SAM (CisBio), 0.14 mM GpppA RNA cap analogue (New England Biolabs) in reaction buffer consisting of HEPES-KOH pH 7.6, 150 mM NaCl, and 0.5 mM DTT. The reaction was started with the addition of nsp10–14 and was allowed to proceed for 20 min before quenching by the addition of 2 μl 5 M NaCl to a final concentration of 1 M.

Following quenching, 2 μl Detection Buffer 1 (CisBio) was immediately added to the reaction mixture. After 10 min, 4 μl of 16× SAH-d2 conjugate solution (CisBio) was added. 16× SAH-d2 was prepared by adding one part SAH-d2 to 15 parts Detection Buffer 2 (CisBio). After 5 min, 4 μl of 1× α-SAH Tb Cryptate antibody solution was added to the reaction mixture. 1× α-SAH Tb Cryptate antibody solution was prepared by adding one part α-SAH Tb Cryptate antibody (CisBio) to 49 parts Detection Buffer 2 (CisBio).
Homogenous time-resolved fluorescence (HTRF) measurements were taken after 1 h following α-SAH Tb Cryptate antibody addition on a Tecan Infinite M1000 Pro plate reader. Readings were taken with a lag time of 60 μs after excitation at λ = 337 nm. Readings were taken at emission wavelengths of λ = 665 nm and λ = 620 nm. The experimental HTRF ratio (HTRF$_{exp}$) was then calculated as the ratio of emission intensities: λ = 665/λ = 620. To reach the normalised HTRF ratio, HTRF ratio measurements were also taken of wells without enzyme ($E_0$) and without SAH-d2 ($d_20$), representing the maximum and minimum achievable HTRF values, respectively. The normalised HTRF ratio was then calculated as a linear transformation of the experimental HTRF ratio, the $E_0$ ratio, and the $d_20$ ratio:

$$\text{Normalised HTRF} = \frac{\text{HTRF}_{exp} - d_20}{E_0 - d_20}$$

### Screening library

The high-throughput screening was performed using a custom compound collection assembled from commercial sources (Sigma, Selleck, Enzo, Tocris, Calbiochem, and Symansis). The complete list of chemicals included in the custom library and their descriptions can be found in Zeng et al. [42]. 2.5 or 7.5 ml of a 10 mM stock of the compounds dissolved in DMSO were arrayed and dispensed into square flat-bottom black 384-well plates containing 1 μl DMSO/well using an Echo 550 (Labcyte), before being sealed and stored at −80°C.

### RiboGreen-based screen (first)

All steps and reagents were kept at room temperature (RT) during the day of the screen. The morning of the screen all plates were moved from −80°C to 4°C. From there, plates were moved to RT 30 min before centrifuging and de-sealing. The RiboGreen-based screen was performed in three main steps which required the use of three independent XRD-384 Reagent Dispensers (FluidX Ltd.) each loaded with 16-channel tubing and set at high speed. First, 10 μl of 2× enzyme mix (10 nM nsp10–14 fusion protein in 1× reaction buffer 1) was dispensed in columns 1–23 and incubated ‘Enzyme + drugs’ for 10 min. After each dispensing, plates were centrifuged for <1 min at 4000 rpm. Second, 10 μl of 2× substrate mix (100 nM unlabelled dsRNA substrate in 1× reaction buffer 1) was dispensed in columns 2–24, and 10 μl reaction buffer 1 were pipetted by hand to control columns 1 and 24. After 5 min, 30 μl of Stop/RiboGreen mix (final concentration in 50 μl: 25 mM Tris–HCl pH 7.5, 0.1 mg/ml BSA, 20 mM EDTA and a 4000-fold dilution of Quant-iT™ RiboGreen® RNA reagent) was dispensed in columns 1–24. After 2 min, fluorescence in all wells was read using a Spark Multimode microplate reader (Tecan) with the following settings: Excitation 485 nm/Emission 530 nm (20/20 bandwidth), Gain 94, 30 flashes, Z position of 18843. Plates were processed one after the other, with ~7 min delay between them.

### Cy3/quencher-based kinetic screen (second)

All steps and reagents were kept at RT during the days of the screen except the stock of enzyme mix that was kept in ice. The morning of the screen, all plates were moved from −80°C to 4°C. From there, plates were moved to room temperature for 30 min before centrifuging and de-sealing. This second screen was performed in two main steps which required the use of two independent XRD-384 Reagent Dispensers (FluidX Ltd.) each loaded with 16-channel tubing and set at high speed. First, 10 μl of 2× enzyme mix (1 nM nsp10–14 fusion enzyme in 1× reaction buffer 2) was dispensed in columns 1–23, and 10 μl reaction buffer 2 were pipetted by hand to control columns 1 and 24. After 10 min, 10 μl of 2× substrate mix (100 nM Cy3/quencher RNA substrate in 1× reaction buffer 2) was dispensed in columns 2–24 and, after 2 min, started reading fluorescence in all wells every 1 min for 10 min using a Spark Multimode microplate reader (Tecan) with the following settings: Excitation 545 nm/Emission 575 nm (10/10 bandwidth), Gain 147, 10 flashes, Z position of 17800. Plates were processed one after the other, with ~20 min delay between them.

### Screen data analysis

Screen data were analysed with custom MATLAB and R scripts. For the RiboGreen screen, normalised residual activity was calculated for each well, relative to the controls on that plate. The median background fluorescence, calculated from eight wells containing no substrate, was subtracted from all wells, before normalisation using.
the formula:

\[ 1 - \frac{M_{\text{max}} - x}{M_{\text{max}} - M_{\text{min}}} \]

where \( M_{\text{max}} \) is the median of eight wells without enzyme (maximum signal), \( M_{\text{min}} \) is the median of 16 wells with no drug (minimum signal) and \( x \) is the experimental value.

For the second Cy3/quencher-based screen, the slope of each reaction over the first 6 min was calculated by linear regression and then was normalised by dividing by the average of the control wells without drugs in each row of the plate.

In both screens, \( Z \) scores were then calculated for each experimental well.

\[ Z = \frac{x - M_{\text{all}}}{\sigma_{\text{all}}} \]

where \( x \) is the normalised experimental value, and \( M_{\text{all}} \) and \( \sigma_{\text{all}} \) are the median and standard deviation of all 6106 normalised samples at that concentration, respectively.

\( Z' \) factors were calculated for each plate to determine screen quality.

\[ Z' = 1 - \frac{3\sigma_{\text{pos}} + 3\sigma_{\text{neg}}}{|\mu_{\text{pos}} - \mu_{\text{neg}}|} \]

where \( \mu_{\text{pos}} \) and \( \sigma_{\text{pos}} \) are the mean and standard deviation of the positive controls (no drugs), respectively, and \( \mu_{\text{neg}} \) and \( \sigma_{\text{neg}} \) are the mean and standard deviation of the negative controls (no enzyme), respectively.

**\( K_M \) and IC\(_{50} \) calculation**

For the unlabelled dsRNA substrate, we calculated the initial velocity of the reactions considering 0, 3 and 6 min in the presence of 5 nM of nsp10–14 fusion protein and 15.65–250 nM substrate by linear regression. Slopes were then used to calculate \( K_M \) and \( V_{\text{MAX}} \) by non-linear fitting to the Michaelis–Menten equation using GraphPad Prism.

For the Cy3-dsRNA substrate, we determined the maximum velocity over the first 45 min of the reactions in the presence of 0.5 nM of nsp10–14 fusion protein and 15.65–500 nM substrate by calculating the maximum of the first derivative. Slopes were then used to calculate \( K_M \) and \( V_{\text{MAX}} \) by non-linear fitting to the Michaelis–Menten equation using GraphPad Prism.

Similarly, we determined the maximum velocity of the reactions in the presence of 0.5 nM nsp10–14, 50 nM Cy3/Q-substrate and a titration of patulin or ATA (0–160 \( \mu \)M) over 15 min by calculating the maximum of the first derivative. Slopes were then used to calculate the percentage of activity relative to the slope without inhibitor. Percent activity for each log\(_{10} \) of the concentration of patulin or ATA were then used to estimate the IC\(_{50} \) and Hill slopes using GraphPad Prism.

**SARS-CoV-2 production**

Batches of the BetaCoV/England/02/2020 (Public Health England) strain of the SARS-CoV-2 virus were produced as in our accompanying manuscripts using VERO E6 cells (see Zeng et al. \[42\]). A 6-well plate plaque assay was then used to determine plaque-forming units (PFU) per ml.

**Viral infectivity assay**

Viral infectivity assays were performed as in our accompanying manuscripts. Briefly, 96-well imaging plates (Greiner 655090) were seeded with VERO E6 cells and cultured overnight. The next day, the media was replaced with fresh growth media, followed by the addition of drug compounds. Finally, the cells were infected by SARS-CoV2 with a final MOI of 0.5 PFU/cell. Twenty-two hours post-infection, cells were fixed, permeabilised, and stained for SARS-CoV2 N protein using Alexa488-labelled-CR3009 antibody and cellular DNA using DRAQ7 (ABCAM). Imaging was carried out using an Opera Phenix (PerkinElmer) and fluorescent areas and
intensity calculated using the Phenix-associated software Harmony (PerkinElmer). Alexa488/N intensities were normalised to DRAQ7/DNA, and to vehicle only samples.

Data Availability Statement
All data associated with this paper has been deposited in FigShare (10779/crick.14518686). Data deposited in FigShare include the results from both screens and the raw data of the experiments. The complete list of chemicals in the custom library and their descriptions can be found in Zeng et al. [42].

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Funding
This work was supported by the Francis Crick Institute, which receives its core funding from Cancer Research U.K. (FC001066), the U.K. Medical Research Council (FC001066), and the Wellcome Trust (FC001066). This work was also funded by a Wellcome Trust Senior Investigator Award (106252/Z/14/Z) to J.F.X.D. J.Z. has received funding from a Ph.D. fellowship awarded by Boehringer Ingelheim Fonds. BC and FW have received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement Nos. 895786 and 844211. T.D.D. has received funding from the Wellcome Trust under the Sir Henry Wellcome Postdoctoral Fellowship agreement No. 204678/Z/16/Z.

Acknowledgements
We thank the Crick high-throughput screen (HTS) science technology platform (STP) for providing the chemical library and for help with screen design and analysis and are grateful to MRC Reagents and Services (https://mrcppureagents.dundee.ac.uk/) for providing DU70487 DNA construct for nsp14 and Karim Labib for providing the pFGET19-Ulp1 construct. We thank the Fermentation unit of the Crick Structural biology STP for large scale protein expression. We thank David McClure for help with screen analysis. We thank Anne Early for ordering supplies and hit compounds. We thank Chris Smith for help with the initial screen design and concepts.

Abbreviations
ATA, aurintricarboxylic acid; dsRNA, double-strand RNA; HTRF, homogenous time-resolved fluorescence; nsp, non-structural proteins; ORF, open reading frames; PFU, plaque-forming units; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

References
1. Coronavirus Study Group of the International Committee on Taxonomy of Viruses. (2020) The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544 https://doi.org/10.1038/s41564-020-0669-z
2. Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W. et al. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 https://doi.org/10.1038/s41586-020-2012-7
3. Xiong, T.Y., Redwood, S., Prendergast, B. and Chen, M. (2020) Coronaviruses and the cardiovascular system: acute and long-term implications. Eur. Heart J. 41, 1798–1800 https://doi.org/10.1093/eurheartj/ehaa231
4. Zhao, Y.M., Shang, Y.M., Song, W.B., Li, Q.Q., Xie, H., Xu, Q.F. et al. (2020) Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 25, 100463 https://doi.org/10.1016/j.eclinm.2020.100463
5. Encabo H. I., Gray, W., Garcia-Abelmoz, M., Wood, H., Ulferts, R., Aramburu, I. V. et al. (2021) Human erythroid progenitors are directly infected by SARS-CoV-2: implications for emerging erythropoiesis in severe COVID-19 patients. Stem Cell Rep. 16, 428–436 https://doi.org/10.1016/j.stemcr.2021.02.001
6. Hu, B., Guo, H., Zhou, P. and Shi, Z.-L. (2021) Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141–154 https://doi.org/10.1038/s41579-020-00450-7
7. Totura, A.L. and Bavari, S. (2019) Broad-spectrum coronavirus antiviral drug discovery. Expert Opin. Drug Discov. 14, 397–412 https://doi.org/10.1080/17460441.2019.1581171
8. Medline, A., Hayes, L., Valdez, K., Hayashi, A., Vahedi, F., Capell, W. et al. (2020) Evaluating the impact of stay-at-home orders on the time to reach the peak burden of Covid-19 cases and deaths: does timing matter? BMC Public Health 20, 1750 https://doi.org/10.1186/s12889-020-09817-9
9. Cui, J., Li, F. and Shi, Z.-L. (2019) Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181–192 https://doi.org/10.1038/s41579-018-0118-9
10. Peiris, J.S., Lai, S.T., Poon, L.L., Guan, Y., Yam, L.Y., Lim, W. et al. (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319–1325 https://doi.org/10.1016/S0140-6736(03)13077-2
11. Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D. and Fouchier, R.A. (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814–1820 https://doi.org/10.1056/NEJMoa1211721
40 Ashburn, T.T. and Thor, K.B. (2004) Drug repositioning: identifying and developing new uses for existing drugs.

39 Gribble, J., Stevens, L.J., Agostini, M.L., Anderson-Daniels, J., Chappell, J.D., Lu, X. et al. (2021) The coronavirus proofreading exoribonuclease

16 Pan, H., Peto, R., Henao-Restrepo, A.M., Preziosi, M.P., Sathiyamoorthy, V., Abdool Karim, Q. et al. (2021) Repurposed antiviral drugs for Covid-19 – interim WHO solidarity trial results. N. Engl. J. Med. 384, 497–511 https://doi.org/10.1056/NEJMoa2123184

V’Kovski, P., Kratzel, A., Steiner, S., Staelder, H. and Thié, V. (2020) Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155–170 https://doi.org/10.1038/s41579-020-00468-6

Finkel, Y., Mizrahi, O., Nachshon, A., Weingarten-Gabbay, S., Morgenstern, D., Yahalom-Ronen, Y. et al. (2021) The coding capacity of SARS-CoV-2. Nature 589, 125–129 https://doi.org/10.1038/s41586-020-2739-1

Sevajol, M., Subissi, L., Decroly, E., Canard, B. and Imbert, I. (2014) Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus. Virus Res. 194, 90–99 https://doi.org/10.1016/j.virusres.2014.10.008

Minskaia, E., Hertzig, T., Gorbalenya, A.E., Campanacci, V., Cambillau, C., Canard, B. et al. (2006) Discovery of an RNA virus 3’-5’ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc. Natl Acad. Sci. U.S.A. 103, 5108–5113 https://doi.org/10.1073/pnas.0508200103

Chen, Y., Cai, H., Pan, J., Xiang, N., Tian, P., Ahola, T. et al. (2009) Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase. Proc. Natl Acad. Sci. U.S.A. 106, 3484–3489 https://doi.org/10.1073/pnas.0808790106

Bouvet, M., Debaron, C., Imbert, I., Selisko, B., Snijder, E.J., Canard, B. et al. (2010) In vitro reconstitution of SARS-coronavirus RNA cap methylation. PLoS Pathog. 6, e1000863 https://doi.org/10.1371/journal.ppat.1000863

Ma, Y., Wu, L., Shaw, N., Gao, Y., Wang, J., Sun, Y. et al. (2015) Structural basis and functional analysis of the SARS coronavirus nsp4-nsp10 complex. Proc. Natl Acad. Sci. U.S.A. 112, 9436–9441 https://doi.org/10.1073/pnas.1508686112

Moser, M.J., Holley, W.R., Chatterjee, A. and Mian, I.S. (1997) The proofreading domain of Escherichia coli DNA polymerase I and other DNA and/or RNA exoribonuclease domains. Nucleic Acids Res. 25, 5110–5119 https://doi.org/10.1093/nar/25.12.5110

Zuo, Y. and Deutscher, M.P. (2001) Exoribonuclease superfamilies: structural analysis and phylogenetic distribution. Nucleic Acids Res. 29, 1017–1026 https://doi.org/10.1093/nar/29.5.1017

Bouvet, M., Imbert, I., Subissi, L., Glaiss, L., Canard, B. and Decroly, E. (2012) RNA 3’-end mismatch excision by the severe acute respiratory coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex. Proc. Natl Acad. Sci. U.S.A. 109, 9372–9377 https://doi.org/10.1073/pnas.1201130109

Gorbalenya, A.E., Enjuanes, L., Ziebuhr, J. and Snijder, E.J. (2006) Nodivirales: evolving the largest RNA virus genome. Virus Res. 117, 17–37 https://doi.org/10.1016/j.viruses.2006.01.017

Eckerle, L.D., Lu, X., Sperry, S.M., Choi, L. and Denison, M.R. (2007) High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. J. Virol. 81, 12315–12319 https://doi.org/10.1128/JVI.01296-07

Smith, E.C., Blanc, H., Surdel, M.C., Vignuzzi, M. and Denison, M.R. (2013) Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutic implications. PLoS Pathog. 9, e1003565 https://doi.org/10.1371/journal.ppat.1003565

Graepel, K.W., Lu, X., Case, J.B., Sexton, N.R., Smith, E.C. and Denison, M.R. (2017) Proofreading-deficient coronaviruses adapt for increased fitness over long-term passage without reversion of exoribonuclease-inactivating mutations. mBio 8, e01503-17 https://doi.org/10.1128/mBio.01503-17

Ôgando, N.S., Ferron, F., Decroly, E., Canard, B., Posthuma, C.C. and Snijder, E.J. (2019) The curious case of the nidosivirus exoribonuclease: its role in RNA synthesis and replication fidelity. Front. Microbiol. 10, 1813 https://doi.org/10.3389/fmicb.2019.01813

Smith, E.C., Case, J.B., Blanc, H., Isakow, O., Shemon, N., Vignuzzi, M. et al. (2015) Mutations in coronavirus nonstructural protein 10 decrease virus replication fidelity. J. Virol. 89, 6418–6426 https://doi.org/10.1128/JVI.00319-15

Eckerle, L.D., Becker, M.M., Halpin, R.A., Li, K., Venter, E., Lu, X. et al. (2010) Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog. 6, e1000896 https://doi.org/10.1371/journal.ppat.1000896

Subissi, L., Posthuma, C.C., Collet, A., Zevzenhoven-Dobbe, J.C., Gorbalenya, A.E., Decroly, E. et al. (2014) One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exoribonuclease activities. Proc. Natl Acad. Sci. U.S.A. 111, E3900–9 https://doi.org/10.1073/pnas.1323705111

Yan, L., Ge, J., Zheng, L., Zhang, Y., Gao, Y., Wang, T. et al. (2021) Cryo-EM structure of an extended SARS-CoV-2 replication and transcription complex reveals an intermediate state in SARS-CoV-2 replication. Cell 184, 184–93.e10 https://doi.org/10.1016/j.cell.2020.11.016

Ôgando, N.S., Zevzenhoven-Dobbe, J.C., van der Meer, Y., Breidenbeek, P.J., Posthuma, C.C. and Snijder, E.J. (2020) The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2. J. Virol. 94, e01246-20 https://doi.org/10.1128/JVI.01246-20

Becares, M., Pascual-Iglesias, A., Nogales, A., Solà, I., Enjuanes, L. and Zuniga, S. (2016) Mutagenesis of coronavirus nsp14 reveals its potential role in modulation of the innate immune response. J. Virol. 90, 5399–5414 https://doi.org/10.1128/JVI.03259-15

Case, J.B., Li, Y., Elliott, R., Lu, X., Graepel, K.W., Sexton, N.R. et al. (2018) Murine hepatitis virus nsp14 exoribonuclease activity is required for resistance to innate immunity. J. Virol. 92, e01531-17 https://doi.org/10.1128/JVI.01531-17

Gröbli, J., Stevens, L.J., Agostini, M.L., Anderson-Daniels, J., Chappell, J.D., Lu, X. et al. (2021) The coronavirus proofreading exoribonuclease mediates extensive viral recombination. PLoS Pathog. 17, e1009226 https://doi.org/10.1371/journal.ppat.1009226

Ashburn, T.T. and Thor, K.B. (2004) Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673–683 https://doi.org/10.1038/nrd1468

Guy, R.K., DiPaola, R.S., Romanelli, F. and Dutch, R.E. (2020) Rapid repurposing of drugs for COVID-19. Science 368, 829–830 https://doi.org/10.1126/science.abb9332

Zeng, J., Weissmann, F., Bertolin, A.P., Posse, V., Posse, V. et al. (2021) Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase. Biochem. J. 478, 2405–2423 https://doi.org/10.1042/BCJ20210201
60 Yuen, C.K., Lam, J.Y., Wong, W.M., Mak, L.F., Wang, X., Chu, H. et al. (2020) SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent
59 Xu, L., Khadijah, S., Fang, S., Wang, L., Tay, F.P. and Liu, D.X. (2010) The cellular RNA helicase DDX1 interacts with coronavirus nonstructural protein
44 Zeng, J., Weissmann, F., Bertolin, A.P., Posse, V., Canal, B., Ufferts, R. et al. (2021) Identifying SARS-CoV-2 antiviral compounds by screening for small
43 Irwin, J.J., Duan, D., Torosyan, H., Doak, A.K., Ziebart, K.T., Sterling, T. et al. (2015) An aggregation advisor for ligand discovery. J. Med. Chem. 58,
42 Zaramago, M., Bárria, C., Costa, V., Souza, C.S., Vieigas, S.C., Domingues, S. et al. (2021) New targets for drug design: importance of nsp14/nsp10
41 Basu, S., Mak, T., Ufferts, R., Wu, M., Deegan, T., Fujisawa, R. et al. (2021) Identifying SARS-CoV-2 antiviral compounds by screening for small
40 Zheng, W., Sun, W. and Simeonov, A. (2018) Drug repurposing screens and synergistic drug-combinations for infectious diseases.
39 McGovern, S.L., Caselli, E., Grigorieff, N. and Shoichet, B.K. (2002) A common mechanism underlying promiscuous inhibitors from virtual and high-
38 Hallick, R.B., Chelm, B.K., Gray, P.W. and Orozco, Jr, E.M. (1977) Use of aurintricarboxylic acid as an inhibitor of nucleases during nucleic acid
37 Park, J.G., Ávila-Pérez, G., Madere, F., Hilimire, T.A., Nogales, A., Almazán, F. et al. (2019) Potent inhibition of Zika virus replication by aurintricarboxylic
36 He, R., Adonov, A., Traykova-Adonova, M., Cao, J., Cutts, T., Grudesky, E. et al. (2004) Potent and selective inhibition of SARS coronavirus replication
35 Klein, P., Crioni, O., Giacomelli, A. and Scalliet, G. (2008) In vitro and in vivo activity of aurintricarboxylic acid preparations against Cryptosporidium
34 Park, J.G., Cirioni, O., Giacomelli, A. and Scalliet, G. (2009) Evaluation of patulin toxicity in the thymus of growing male rats. Artic. Hig. Rada Toksikol. 60,
33 Saxena, N., Ansari, K.M., Kumar, R., Chaudhari, B.P., Dwivedi, P.D. and Das, M. (2011) Role of mitogen activated protein kinases in skin tumorigenicity of
32 Saramago, M., Bárria, C., Costa, V.G., Souza, C.S., Viegas, S.C., Domingues, S. et al. (2021) New targets for drug design: importance of nsp14/nsp10
31 Irwin, J.J., Duan, D., Torosyan, H., Doak, A.K., Ziebart, K.T., Sterling, T. et al. (2015) An aggregation advisor for ligand discovery. J. Med. Chem. 58,
30 Lim, C.T., Tan, K.W., Wu, M., Ulferts, R., Armstrong, L.A., Ozono, E. et al. (2021) Identifying SARS-CoV-2 antiviral compounds by screening for small
29 Zheng, W., Sun, W. and Simeonov, A. (2018) Drug repurposing screens and synergistic drug-combinations for infectious diseases.
28 Hallick, R.B., Chelm, B.K., Gray, P.W. and Orozco, Jr, E.M. (1977) Use of aurintricarboxylic acid as an inhibitor of nucleases during nucleic acid
73 Saxena, N., Ansari, K.M., Kumar, R., Dhawan, A., Dwivedi, P.D. and Das, M. (2009) Patulin causes DNA damage leading to cell cycle arrest and apoptosis through modulation of Bax, p(53) and p(21/WAF1) proteins in skin of mice. *Toxicol. Appl. Pharmacol.* **234**, 192–201 https://doi.org/10.1016/j.taap.2008.09.033

74 Seigle-Murandi, F., Steiman, R., Krivobok, S., Beriel, H. and Benoit-Guyod, J.L. (1992) Antitumor activity of patulin and structural analogs. *Pharmazie* **47**, 288–291 PMID: 1518888

75 Clarke, M. (2006) The 1944 patulin trial of the British Medical Research Council. *J. R. Soc. Med.* **99**, 478–480 https://doi.org/10.1177/014107680609900923

76 Stein, A., Ruggiano, A., Carvalho, P. and Rapoport, T.A. (2014) Key steps in ERAD of luminal ER proteins reconstituted with purified components. *Cell* **158**, 1375–1388 https://doi.org/10.1016/j.cell.2014.07.050

77 Weissmann, F., Potzold, G., VanderLinden, R., Huin In 't Veld, P.J., Brown, N.G., Lampert, F. et al. (2016) biGBac enables rapid gene assembly for the expression of large multisubunit protein complexes. *Proc. Natl Acad. Sci. U.S.A.* **113**, E2564–E2569 https://doi.org/10.1073/pnas.1604935113

78 Trowitzsch, S., Bienossek, C., Nie, Y., Garzoni, F. and Berger, I. (2010) New baculovirus expression tools for recombinant protein complex production. *J. Struct. Biol.* **172**, 45–54 https://doi.org/10.1016/j.jsb.2010.02.010